First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

We are excited to see efti in combination with KEYTRUDA now driving a 1.9-fold increase in responses ... The ESMO Proferred ...

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...

PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...

Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (21%) of patients experienced 90-100% tumor shrinkage VERSATILE-003 Phase 3 clinical ...

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of ...

Cytovation to present safety and efficacy data from CICILIA phase I/IIa clinical trial evaluating CY-101 in solid tumors: Bergen, Norway Monday, September 16, 2024, 18:00 Hrs [IST ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

PADCEV + KEYTRUDA**: additional analysis from the pivotal EV-302 ... PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors Yap et al Poster Presentation (Abstract 413P) Monday, ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the ...

The data were presented during a poster session on September 14 at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. As of the latest data cut of the VERSATILE ...